Why the study?
Does intravenous flecainide safely suppress premature ventricular and atrial contractions in hospitalized patients with arrhythmias?
Does intravenous flecainide safely suppress premature ventricular and atrial contractions in hospitalized patients with arrhythmias?
Intravenous flecainide effectively suppresses premature ventricular and atrial contractions without causing significant ECG interval prolongation or major side effects.
Answers are grounded in this paper and cite their sources.
IV flecainide may suppress PVCs/PACs in select inpatients; hypothesis-generating case report leaves open confirmation in controlled trials.
A new class I antiarrhythmic, flecainide, was investigated in 10 patients to assess short-term efficacy and safety. All patients were hospitalized for 3 days; no antiarrhythmics were given on days 1 and 3. On day 2 flecainide 1 mg/kg was given intravenously over 5 min. If the predrug arrhythmia(s) was not completely suppressed, additional boluses of 0.5 mg/kg were injected at 30- to 60-min intervals to a maximum of 5 mg/kg. Seven patients received 2 mg/kg, and 3 patients received 1 mg/kg. Before drug 5 patients had premature ventricular contractions (PVCs) (more than 4 per min); 2 patients had atrial fibrillation (AF) with PVCs; 1 patient had both PVCs and premature atrial contractions (PACs); and 2 patients had only PACs. One patient with PVCs failed to respond to flecainide; he was unresponsive to all available antiarrhythmic drugs. In the other 7 patients PVCs were suppressed for an average of 13 hr (range 6 to 24 hr), AF was not affected, and PACs were suppressed. Flecainide did not induce significant changes in P-R, QRS, or Q-T intervals. Side effects were negligible and included a tingling sensation and feeling of skin warmth for 15 min after drug in one patient.
No takes yet. Share an insight, caveat, or question.
Pitambar Somani (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: